Aeterna Zentaris Inc (AEZS)

0.430
0.000(0.00%)
  • Volume:
    33,020
  • Bid/Ask:
    0.420/0.430
  • Day's Range:
    0.420 - 0.440
  • Type:Equity
  • Market:Canada
  • ISIN:CA0079754028
  • CUSIP:007975402

AEZS Overview

Prev. Close
0.43
Day's Range
0.42-0.44
Revenue
5.22M
Open
0.435
52 wk Range
0.42-4.63
EPS
-0.08
Volume
33,020
Market Cap
52.2M
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
78,998
P/E Ratio
-
Beta
2
1-Year Change
-51.14%
Shares Outstanding
121,397,007
Next Earnings Date
Mar 02, 2022
What is your sentiment on Aeterna Zentaris Inc?
or
Market is currently closed. Voting is open during market hours.

Aeterna Zentaris Inc Company Profile

Employees
12
Market
Canada

Aeterna Zentaris Inc. is a specialty biopharmaceutical company. The Company is focused on developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products focused on areas of significant unmet medical need. Its business is to finalize the development, manufacturing, registration and commercialization of Macrilen (macimorelin). Macrilen (macimorelin) is an orally available peptidomimetic ghrelin receptor agonist that stimulates the secretion of growth hormone by binding to the ghrelin receptor (GHSR-1a) and that has potential uses in both endocrinology and oncology indications. Macimorelin is the oral test indicated for the diagnosis of adult growth hormone deficiency (AGHD). The Company is leveraging the clinical and compelling safety profile of macimorelin in developing diagnosis of childhood-onset growth hormone deficiency (CGHD) in collaboration with Novo Nordisk.

Read More

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesNeutralSellSellStrong SellStrong Sell
Technical IndicatorsBuyBuyStrong SellStrong SellStrong Sell
SummaryNeutralNeutralStrong SellStrong SellStrong Sell
  • Sale una nueva variante y no veas la k se lía
    0
    • why is this 🚀?
      0
      • There is hype on new COVID treatment announcement and it is/was oversold
        0
    • Seeing a lot of predictions for 3.50 in the next few days
      0
      • why?
        0
    • let's get that oral vaccine out
      1
      • Than ?
        0
        • It's spelled -ess h eye tee-
          1
          • I used to be an enthusiastic bag holder too,...,woke up,dumped the ****
            0
            • https://www.handelsblatt.com/dpa/wirtschaft-handel-und-finanzen-verband-corona-impfstoffe-zweiter-generation-vielleicht-schon-2021/27222440.html?ticket=ST-5153637-HIXgEEndEVksGk2n6CrC-ap2
              0
              • https://www.zentaris.com/oral-coronavirus-vaccine
                0
                • I want to dump my position of this garbage as soon as possible. Been holding since right after the run up in Feb., got in low, but, I don't care. They could have a PR that announced they found a cure for both aging and cancer, and their share price would still be ********
                  1
                  • Financials are not favorable, but for some reason I'm considering a risk on this one.
                    0
                    • use a real name, ****
                      0
                  • awesome quarter
                    0
                    • It managed to outperform the Markets overall today, if we are willing to accept sideways as an outperform.
                      0
                      • well done aezs
                        0
                        • Rename it "Sideways International Inc."
                          0
                          • fantastic company
                            0
                            • Preclinical trials will likely be completed first. AEZS would then identify the Lead Candidate. An new drug application (IND) would then likely be submitted to the FDA. Once the IND is approved, then Phase 1 trials should begin. When the IND is submitted, the company should announce this to shareholders. Once the IND is approved, this should also be announced to shareholders.
                              0
                              • I think the company will go through Germany's FDA and not the USA one
                                0
                              • Probably both as US & EU has friendly relations. The thing is, they need to speed up a bit to normalized the global pandemic.
                                0
                            • Any thoughts on when the Covid application was submitted. I assume at the same time Aezs signed the license agreement with the uni. Typical response from the gov. Agency for trials is around two months. That puts us around middle of May. Please intelligent comments.
                              0
                              • The next VXRT...........Aeterna Zentaris Appoints Michael Teifel, Ph.D. as Senior Vice President, Non-Clinical Development and Chief Scientific Officer
                                0
                                • https://www.eurekalert.org/pub_releases/2021-04/uow-cdf042721.php
                                  0
                                  • https://www.eurekalert.org/pub_releases/2021-04/uow-cdf042721.php
                                    0
                                    • I agree 100%
                                      0
                                      • Some sort of upbeat PR would be awfully nice to get this ***up on its feet, been laying here and descending for the past two months,...,uhg.
                                        0
                                        • POS
                                          0
                                      • This company sucks. it was a nice PR piece on the vaccine, but until they actually roll out something and stop wasting investor money, its going to $.01
                                        2
                                        • It would be nice if Citadel would stop manipulating share prices, wouldn't it ?.
                                          0
                                          Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
                                          Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.